Scandinavian Real Heart AB (SE:HEART)
:HEART
Want to see SE:HEART full AI Analyst Report?
Top Page
Scandinavian Real Heart AB
(HEART)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr18.50
▼(-28.29% Downside)
Action:Reiterated
Date:05/08/26
The score is held down primarily by weak financial performance (minimal revenue, heavy losses, and ongoing cash burn with financing/dilution risk). Technicals are a partial offset with a strong uptrend and positive momentum, but near-overbought RSI reduces confidence. Valuation contributes little due to an uninformative P/E and no dividend yield.
Positive Factors
Low leverage / modest debt
Low reported leverage provides durable financial flexibility for a capital-intensive medtech developer. With limited fixed interest obligations, the company can prioritize clinical milestones and regulatory work without large debt service constraints, reducing near-term insolvency risk.
Negative Factors
Pre-revenue with persistent losses
Being effectively pre-revenue with sustained deep losses is a structural risk: the business must deliver clinical and regulatory milestones to ever achieve commercial sales. Continued operating losses increase execution risk and lengthen the time until self-sustaining cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / modest debt
Low reported leverage provides durable financial flexibility for a capital-intensive medtech developer. With limited fixed interest obligations, the company can prioritize clinical milestones and regulatory work without large debt service constraints, reducing near-term insolvency risk.
Read all positive factors
Scandinavian Real Heart AB (HEART) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr151.69M
Dividend YieldN/A
Average Volume (3M)7.92K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue GrowthN/A
EPS Growth68.59%
CountrySE
Employees13
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-16.57
Shares Outstanding8,497,797
10 Day Avg. Volume3,221
30 Day Avg. Volume7,918
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr42.00M
Scandinavian Real Heart AB Business Overview & Revenue Model
Company Description
Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. It engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, PulsePump, and Sternal Prosthesis products. The company was incorpo...
How the Company Makes Money
null...
Scandinavian Real Heart AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 0.00 |
| Gross Profit | 28.33M | -20.40M | -164.70K | -50.22M | 12.29M | 7.20M |
| EBITDA | -14.02M | -15.09M | -33.54M | -67.25M | -13.73M | -10.09M |
| Net Income | -38.87M | -35.50M | -34.35M | -67.98M | -13.99M | -10.48M |
Balance Sheet | ||||||
| Total Assets | 87.94M | 72.69M | 83.28M | 102.64M | 119.82M | 117.82M |
| Cash, Cash Equivalents and Short-Term Investments | 27.94M | 16.57M | 23.72M | 43.30M | 11.26M | 42.67M |
| Total Debt | 5.40M | 4.46M | 6.35M | 8.25M | 2.17M | 2.80M |
| Total Liabilities | 13.59M | 10.20M | 15.94M | 20.60M | 22.17M | 6.53M |
| Stockholders Equity | 74.35M | 62.49M | 67.34M | 82.04M | 97.65M | 111.29M |
Cash Flow | ||||||
| Free Cash Flow | -39.30M | -16.53M | -38.25M | -26.82M | -31.14M | -29.24M |
| Operating Cash Flow | -12.62M | -15.66M | -12.99M | -25.05M | -7.38M | -9.65M |
| Investing Cash Flow | -25.71M | -26.11M | -24.28M | -1.77M | -23.76M | -19.59M |
| Financing Cash Flow | 43.44M | 34.62M | 17.69M | 58.87M | -276.28K | 49.46M |
Scandinavian Real Heart AB Technical Analysis
Positive
25.80
Price Trends
15.34
Positive
14.65
Positive
16.33
Positive
Market Momentum
0.69
Positive
58.04
Neutral
52.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HEART, the sentiment is Positive. The current price of 25.8 is above the 20-day moving average (MA) of 17.61, above the 50-day MA of 15.34, and above the 200-day MA of 16.33, indicating a neutral trend. The MACD of 0.69 indicates Positive momentum. The RSI at 58.04 is Neutral, neither overbought nor oversold. The STOCH value of 52.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:HEART.
Scandinavian Real Heart AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr151.69M | ― | ― | ― | ― | 68.59% | |
46 Neutral | kr57.69M | -0.68 | 437.24% | ― | 268.54% | 94.27% | |
44 Neutral | kr58.72M | -8.36 | ― | ― | -9.56% | 51.30% | |
43 Neutral | kr38.26M | -2.89 | -60.56% | ― | 27.31% | 6.31% | |
41 Neutral | kr48.84M | -2.11 | -50.21% | ― | ― | -104.27% |
* Healthcare Sector Average
SE:HEART
Scandinavian Real Heart AB
17.60
3.60
25.71%
SE:QLIFE
Qlife Holding AB
2.00
-0.18
-8.38%
SE:SPEC
SpectraCure AB
0.08
-0.11
-56.02%
SE:LXB
Luxbright AB
0.15
-0.62
-80.81%
SE:SDOS
ScandiDos AB
1.01
-0.29
-22.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.